Compare Nuwellis Inc (NUWE) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Xylem, Inc. — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Xylem, Inc. trades at $102.3 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 10822.7× Nuwellis Inc's market cap, and Xylem, Inc. pays a 1.69% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Xylem, Inc. for 50 Days on average.
| NUWE | XYL | |
|---|---|---|
Market Cap | $2.20M | $23.81B |
Volume | 121,544 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $146.65 | $152.95 |
52-Week Low | $0.68 | $100.92 |
Typical Hold Time | 26 Days | 50 Days |
Enterprise Value | -$1.52M | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q3 2026 results due October 27. Revenue grew to $9.04B in 2025, with net income margin improving to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump aim to strengthen its industrial water solutions presence.
Outlook remains positive due to strong water-solutions demand and margin expansion, though near-term sentiment is cautious amid China weakness and higher debt from recent note offerings. The consensus price target of $149.13 implies significant upside, but investors should monitor execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
